Could a prostate cancer pill be safer for your heart than a shot?
NCT ID NCT06330805
Summary
This study is comparing two hormone therapies for prostate cancer to see if one is better for heart health. Men with intermediate-risk prostate cancer will receive standard radiation and be randomly assigned to take either a daily pill (relugolix) or get an injection every 3 months (leuprolide) for 6 months. Researchers will measure heart function, fitness, and quality of life before and after treatment to see if there are differences between the two drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.